Original Article SPR064, a pro-drug of paclitaxel, has anti-tumorigenic effects in endometrial cancer cell lines and mouse mode
![Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan | Anticancer Research Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/29/5/1515/F1.large.jpg)
Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan | Anticancer Research
![Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel | Scientific Reports Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-19621-7/MediaObjects/41598_2022_19621_Fig1_HTML.png)
Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel | Scientific Reports
![IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer | Journal for ImmunoTherapy of Cancer IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/10/3/e003924/F1.large.jpg)
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer | Journal for ImmunoTherapy of Cancer
![Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial | Nature Communications Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-26019-y/MediaObjects/41467_2021_26019_Fig1_HTML.png)
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial | Nature Communications
![Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial - ScienceDirect Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2666675822000352-fx1.jpg)
Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial - ScienceDirect
![Frontiers | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review Frontiers | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review](https://www.frontiersin.org/files/Articles/770663/fphar-12-770663-HTML-r1/image_m/fphar-12-770663-g001.jpg)
Frontiers | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
![Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours | Nature Biomedical Engineering Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours | Nature Biomedical Engineering](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41551-022-00949-4/MediaObjects/41551_2022_949_Fig1_HTML.png)
Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours | Nature Biomedical Engineering
![A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice | Translational Psychiatry A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice | Translational Psychiatry](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Ftp.2017.149/MediaObjects/41398_2017_Article_BFtp2017149_Fig1_HTML.jpg)
A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice | Translational Psychiatry
Breast Pathway Group – EC x 4 – Accelerated Paclitaxel x 4: Epirubicin & Cyclophosphamide x 4 followed by Accelerated Pa
![Cancers | Free Full-Text | Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells Cancers | Free Full-Text | Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells](https://www.mdpi.com/cancers/cancers-13-02783/article_deploy/html/images/cancers-13-02783-g001.png)